FRI0611-HPR EUROPEAN PRESCRIBERS’ PERSPECTIVES ON BIOSIMILARS

Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations.

BACKGROUND AND AIM The aim of this survey was to find out the patients' perspectives concerning biosimilars. METHODS An online survey consisting of 14 questions was made available between November 2014 and October 2015. Only respondents who had heard of biosimilars were asked to respond the final twelve questions. RESULTS A total of 1181 patients responded. Of these, 38% had heard of biosim...

Reply to ‘Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers’

Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers

Biosimilars present a necessary and timely opportunity for physicians, patients and healthcare systems. If suitably developed clinically, manufactured to the correct standards and used appropriately, they can positively impact on the financial sustainability of healthcare systems. A critical consideration regarding the introduction of biosimilars into the clinic centres on the required informat...

Biosimilars in oncology: current and future perspectives

The healthcare burden of cancer Cancer places a signifi cant, and growing, burden on healthcare systems around the world. Improved therapies and changing demographics are conspiring to increase the already considerable drain on resources. On the one hand, population growth and ageing will increase the number of new cancer cases in the coming years [1]; on the other, advances in diagnosis and ma...

Perspectives Biosimilars: the science of extrapolation

Since the establishment of a specific approval pathway for similar biological medicinal products, so-called “biosimilars,” several biosimilars have been licensed and become available in the European Union (EU). However, despite a stringent approval process, acceptance of biosimilars in the medical community continues to be low. This appears to be especially true for therapeutic indications, for...